Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.

[1]  G. Ledderose,et al.  Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Lübbert,et al.  Characterization of DNA demethylation effects induced by 5-Aza-2'-deoxycytidine in patients with myelodysplastic syndrome. , 2005, Cancer research.

[3]  H. Kantarjian,et al.  Long‐term follow‐up of a phase I study of high‐dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias , 2003, Cancer.

[4]  H. Trompeter,et al.  Crucial Role of DNA Methylation in Determination of Clonally Distributed Killer Cell Ig-like Receptor Expression Patterns in NK Cells1 , 2002, The Journal of Immunology.

[5]  M. Lübbert,et al.  Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A Ferrant,et al.  Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. , 1995, Blood.

[7]  F. Mandelli,et al.  Pilot study of 5-aza-2'-deoxycytidine (Decitabine) in the treatment of poor prognosis acute myelogenous leukemia patients: preliminary results. , 1993, Leukemia.

[8]  M. Maio,et al.  MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE , 1984, The Lancet.

[9]  Tabershaw Ir,et al.  Benzene and leukaemia. , 1977 .